Who
Tomas Kiselak
Director
Company insider
Files Form 4 as: Director, Viridian Therapeutics; Director and 10% owner, Oruka Therapeutics; Director, Apogee Therapeutics; Director and 10% owner, Jade Biosciences; Director, Zenas BioPharma; Director and 10% owner, Dianthus Therapeutics.
In numbers
- Trades disclosed
- 29
- Buys
- 5
- Sells
- 1
- Bought
- $4.1M
- Sold
- $300.0M
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 27 Oct 2020
- Last trade
- 1 Jul 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 2 Jul 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,341 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,341 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —42,641 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code C | —3,553,410 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $300.0M3,553,410 at $84.43 | filing |
| 9 Jun 2026filed 11 Jun 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,657 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,843 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $3.0M150,000 at $20.00 | filing |
| 17 Sep 2025filed 19 Sep 2025 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code A | $5.0M333,340 at $15.00 | filing |
| 1 Jul 2025filed 2 Jul 2025 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 2 Jun 2025filed 3 Jun 2025 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 19 Nov 2024filed 21 Nov 2024 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —160 at $0.00 | filing |
| 19 Nov 2024filed 21 Nov 2024 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | —160,000 | filing |
| 27 Sep 2024filed 1 Oct 2024 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code J | —62,146 at $0.00 | filing |
| 11 Sep 2024filed 13 Sep 2024 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $3.7M160 at $23,000.00 | filing |
| 11 Sep 2024filed 13 Sep 2024 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code A | $6.3M275,000 at $23.00 | filing |
| 26 Jun 2024filed 28 Jun 2024 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 1 Apr 2024filed 1 Apr 2024 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code J | —58,857 | filing |
| 1 Apr 2024filed 1 Apr 2024 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code J | —58,857 | filing |
| 26 Sep 2023filed 28 Sep 2023 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Bought | $395K30,000 at $13.15 | filing |
News
Head to Head Review: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Zenas BioPharma (NASDAQ:ZBIO)ZBIO · themarketsdaily.com · 18 Oct 2026Head-To-Head Contrast: Zenas BioPharma (NASDAQ:ZBIO) and MacroGenics (NASDAQ:MGNX)ZBIO · themarketsdaily.com · 14 Oct 2026Zenas BioPharma to Host Virtual R&D EventZBIO · manilatimes.net · 6 Oct 2026
0 headlines in the last 90 days name Tomas Kiselak; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.